<DOC>
	<DOCNO>NCT02123823</DOCNO>
	<brief_summary>Phase Ib / II study determine Maximum Tolerated Dose Recommended Phase II Dose , evaluate safety antitumour activity , BI 836845 everolimus combination exemestane woman HR+/HER2- advance breast cancer</brief_summary>
	<brief_title>BI 836845 Estrogen Receptor Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Histologicallyconfirmed locally advance ( aBC ) metastatic breast cancer ( mBC ) deem amenable curative surgery curative radiation therapy Tumors positive estrogenreceptor ( ER ) and/or progesterone receptor ( PgR ) . Tumors must negative HER2 per local lab test . Must adequate archival tumor tissue surgery biopsy . Postmenopausal female patient age &gt; =18 year old . Objective evidence recurrence progressive disease last line systemic therapy breast cancer prior study entry The patient disease refractory nonsteroidal aromatase inhibitor ( letrozole and/or anastrozole ) Patients must : ) Measurable lesion accord RECIST version 1.1 ( R090262 ) b ) Bone lesion : lytic mixed ( lytic + sclerotic ) absence measurable lesion define Eastern Cooperative Oncology Group performance score &lt; = 2 . Life expectancy &gt; = 6 month opinion investigator Fasting plasma glucose &lt; 8.9 mmol/L ( &lt; 160 mg/dL ) HbA1c &lt; 8.0 % Adequate organ function Recovered previous therapy relate toxicity &lt; = Grade 1 study entry ( except stable sensory neuropathy &lt; =Grade 2 alopecia ) Written informed consent consistent ICHGCP guideline local regulation Inclusion criterion biopsy substudy identical main study phase II part except follow two inclusion criterion : Fresh tumor biopsy take deemed safe feasible investigator upon informed consent patient . Bone lesion recommend biopsy Patients eligible undergo tumor biopsy normal coagulation parameter ( INR PTT within normal range ) Exclusion criterion : Previous treatment agent target IGF pathway , phosphoinositide 3kinase ( PI3K ) signal pathway , protein kinase B ( AKT ) , mammalian target rapamycin ( mTOR ) pathways Prior treatment exemestane ( except adjuvant exemestane stop &gt; 12 month prior start study treatment long patient recur within 12 month end adjuvant exemestane ) Known hypersensitivity monoclonal antibody , mTOR inhibitor ( e.g . sirolimus ) , excipients study drug Ovarian suppression ovarian radiation treatment luteinizing hormonereleasing hormone ( LHRH ) agonist Less one week receive immunization attenuate live vaccine prior study treatment Radiotherapy within 4 week prior start study treatment , except case localize radiotherapy analgesic purpose lytic lesion risk fracture complete within two week prior study treatment Chemotherapy , biological therapy ( bevacizumab ) , immunotherapy investigational agent within 5 halflife drug within two week prior start study treatment , whichever longer ; bevacizumab treatment within 4 week prior start study treatment ( criterion concern anticancer therapy ) Hormonal treatment breast cancer within 2 week prior start study treatment Major surgery judgement investigator within 4 week start study treatment schedule surgery project course study Patients receive concomitant immunosuppressive agent chronic corticosteroid use except Topical application , inhale spray , eye drop local injection Patients stable low dose corticosteroid least two week study entry Chronic hepatitis B infection , chronic hepatitis C infection and/or know HIV carrier QTcF prolongation &gt; 470 m QT prolongation deem clinically relevant investigator Disease consider investigator rapidly progress life threaten extensive symptomatic visceral disease include hepatic involvement pulmonary lymphangitic spread tumor History current presence brain CNS metastases Bilateral diffuse lymphangitic carcinomatosis ( lung ) Hypokalemia Grade &gt; 1 History another primary malignancy within 5 year , exception adequately treat insitu carcinoma cervix , uteri , basal squamous cell carcinoma nonmelanomatous skin cancer Family history long QT syndrome Any concomitant serious illness organ system dysfunction opinion investigator would either compromise patient safety interfere evaluation safety antitumor activity test drug ( ) Patients treat drug recognize strong moderate CYP3A4 and/or PgP inhibitor and/or strong CYP3A4 inducer within 2 week prior study entry Patients receive two line chemotherapy locally advanced metastatic breast cancer ( For Phase II : one line )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>